
Mendus Q2 2023 - Funding secured for coming phase II trials

Redeye provides its comment on Mendus' Q2 2023 report. We positively view the company's recent capital raise for continued clinical phase II development of vididencel and ilixadencel. However, it was highly dilutive for shareholders who did not subscribe to their pro-rata share. We finetune estimated clinical timelines for Mendus' drug candidates in our model and thus adjust our estimates and valuation accordingly.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Mendus Q2 2023 - Funding secured for coming phase II trials